5 Results for "

NCI-H1703

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "NCI-H1703" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-132259
CAS No.: 1585973-65-4
Purity:  99.73%
Synonyms: ABT-414
Research Areas:  

Cancer

Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC). Depatuxizumab mafodotin specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used in the study of glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue .
loading...
    loading...
Cat. No.: HY-136704
CAS No.: 1832646-52-2
Purity:  98.5%
Target:  

Glutaminase

Research Areas:  

Cancer

GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC50 of 0.021 μM. GLS1 Inhibitor-1 inhibits the proliferation of PC-3 with an IC50 of 0.3 nM. GLS1 Inhibitor-1 exhibits antitumor efficacy against NCI-H1703 with GI50 of 0.011 μM. GLS1 Inhibitor-1 exhibits moderate pharmacokinetic characteristics .
loading...
    loading...
Cat. No.: HY-149923
CAS No.: 2920221-53-8
Purity:  98.94%
Research Areas:  

Cancer

GPX4-IN-4 (Compound 24) is a potent GPX4 inhibitor. GPX4-IN-4 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-155816
CAS No.: 3033543-95-9
Purity:  99.40%
Target:  

PROTACs

Research Areas:  

Cancer

PROTAC NSD3 degrader-1 (compound 56) is a PROTAC targeting to Nuclear receptor binding SET domain protein NSD3. PROTAC NSD3 degrader-1 specifically induces NSD3 degradation with DC50 values of 1.43 and 0.94 μM in lung cancer cells NCI-H1703 and A549, respectively. PROTAC NSD3 degrader-1 suppresses the methylation of H3K36, induces apoptosis, and causes cell-cycle arrest. PROTAC NSD3 degrader-1 also downregulates the expression of NSD3-associated genes such as CDC25A, ALDH1A1, and IGFBP.
loading...
    loading...
Cat. No.: HY-183635
CAS No.: 1216514-48-5
Target:  

Autophagy

Research Areas:  

Cancer

ELMO2-IN-1 is an ELMO2 inhibitor with a human target Kd of 1.0 µM. ELMO2-IN-1 binds to ELMO2, disrupting its function. ELMO2-IN-1 induces autophagy-dependent cell death. ELMO2-IN-1 can be used for the research of non-small cell lung cancer .
loading...
    loading...